Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. (CLRB): 10 pipeline candidates · ~5 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
5.3 months
D/E 1.92 · 0% dilution
Lead: Phase 2
10 candidates
N/A
2 buys · 0 sells (180d)
A transparent, data-derived signal for Cellectar Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$17.7M
Cash
$8.3M
Quarterly Burn
$4.8M
Runway
5.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| Astatine-211 program | Preclinical |
| CLR 121125 | Phase 1 |
| CLR 121225 | Phase 1 |
| clr 125 | Phase 1 |
| clr 131 | Phase 2 |
| iopofosine I 131 | Phase 2 |
| iopofosine i 131 fractionated dose | Phase 2 |
| iopofosine i 131 multiple dose | Phase 2 |
| iopofosine i 131 single dose | Phase 2 |
| Lead-212 program | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$607K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 163,768 | $416K |
| geode capital management, llc | 52,778 | $134K |
| vanguard fiduciary trust co | 16,573 | $42K |
| blackrock, inc. | 4,745 | $12K |
| vanguard global advisers, llc | 563 | $1K |
| morgan stanley | 510 | $1K |
| td waterhouse canada inc. | 63 | $154 |
| sbi securities co., ltd. | 11 | $28 |
| fmr llc | 10 | $25 |
| jones financial companies lllp | 3 | $8 |
Showing top 10 of 13 institutional holders of Cellectar Biosciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Cellectar Biosciences, Inc.'s pipeline?
Cellectar Biosciences, Inc. (CLRB) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cellectar Biosciences, Inc.'s lead drug candidate?
Cellectar Biosciences, Inc.'s most advanced tracked candidate is Astatine-211 program (Preclinical) for alpha-emitting isotope evaluated in preclinical studies (no specific human indications stated).
What is Cellectar Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cellectar Biosciences, Inc. has approximately 5.3 months of cash runway.
What is Cellectar Biosciences, Inc.'s market capitalization?
Cellectar Biosciences, Inc.'s market capitalization is approximately $17.7M.
Who is the CEO of Cellectar Biosciences, Inc.?
Mr. James V. Caruso is the chief executive officer of Cellectar Biosciences, Inc. (CLRB).
Get the full picture on Cellectar Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.